Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes
James E. Frampton
Drugs (2023) Vol. 83, Iss. 10, pp. 923-934
Open Access | Times Cited: 19

Showing 19 citing articles:

Drug-resistant epilepsy: Definition, pathophysiology, and management
Boulenouar Mesraoua, Francesco Brigo, Simona Lattanzi, et al.
Journal of the Neurological Sciences (2023) Vol. 452, pp. 120766-120766
Closed Access | Times Cited: 36
From barbiturates to ganaxolone: The importance of chirality in drug development and in understanding the actions of old and new antiseizure medications
Meir Bialer, Emilio Perucca
Pharmacology & Therapeutics (2025), pp. 108808-108808
Open Access | Times Cited: 1
Fenfluramine for the treatment of status epilepticus: use in an adult with Lennox–Gastaut syndrome and literature review
Adam Strzelczyk, Hendrik Becker, Lisa Marie Tako, et al.
Neurological Research and Practice (2024) Vol. 6, Iss. 1
Open Access | Times Cited: 5
Activation of sigma-1 receptor ameliorates sepsis-induced myocardial injury by mediating the Nrf2/HO1 signaling pathway to attenuate mitochondrial oxidative stress
Zixuan Li, Jining Zhou, Shengyu Cui, et al.
International Immunopharmacology (2023) Vol. 127, pp. 111382-111382
Closed Access | Times Cited: 12
Fenfluramin in der klinischen Anwendung: neue Therapieoption bei Dravet-Syndrom und Lennox-Gastaut-Syndrom
Hiltrud Muhle, Gerhard Kurlemann, Irina Lehmann, et al.
Deleted Journal (2024) Vol. 37, Iss. 1, pp. 68-78
Open Access | Times Cited: 4
The evolution of antiseizure medication therapy selection in adults: Is artificial intelligence -assisted antiseizure medication selection ready for prime time?
Charlene L. Gunasekera, Joseph I Sirven, Anteneh M. Feyissa
Journal of Central Nervous System Disease (2023) Vol. 15
Open Access | Times Cited: 10
Treatment of Seizures in People with Intellectual Disability
Lance Watkins, Michael Kinney, Rohit Shankar
CNS Drugs (2025)
Closed Access
A post-marketing pharmacovigilance study of Fenfluramine: Adverse event data mining and analysis based on the US Food and Drug Administration Public Data Open Project(openFDA)
Tianyu Chen, Qiying Chen, Yuezhen Zhang, et al.
Pediatric Neurology (2025)
Closed Access
Cenobamate efficacy in specific populations
Pavel Klein
Epilepsia (2025) Vol. 66, Iss. S1, pp. 29-37
Closed Access
Stereoselective Analysis of the Antiseizure Activity of Fenfluramine and Norfenfluramine in Mice: Is l-Norfenfluramine a Better Follow-Up Compound to Racemic-Fenfluramine?
Natalia Erenburg, Emilio Perucca, Jeff Bechard, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2522-2522
Open Access | Times Cited: 3
Reintroducing Fenfluramine as a Treatment for Seizures: Current Knowledge, Recommendations and Gaps in Understanding
Gianluca Dini, Giuseppe Di Cara, Pietro Ferrara, et al.
Neuropsychiatric Disease and Treatment (2023) Vol. Volume 19, pp. 2013-2025
Open Access | Times Cited: 6
Identification of novel and de novo variant in the SCN1A gene confirms Dravet syndrome in Moroccan child: a case report
Hinde El Mouhi, Nada Amllal, Meriame Abbassi, et al.
Molecular Biology Reports (2024) Vol. 51, Iss. 1
Closed Access | Times Cited: 1
Successful use of Fenfluramine in super-refractory status epilepticus in a patient with tuberous sclerosis complex and Lennox-Gastaut syndrome
Thorsten Wildermann, Felicitas Becker, Sarah Jesse, et al.
Epilepsy & Behavior Reports (2024) Vol. 27, pp. 100697-100697
Open Access | Times Cited: 1
Pharmacokinetics of d‐ and l‐norfenfluramine following their administration as individual enantiomers in rats
Natalia Erenburg, Roa’a Hamed, Chanan Shaul, et al.
Epilepsia (2023) Vol. 65, Iss. 2
Closed Access | Times Cited: 2
Stereoselective Analysis of the Antiseizure Activity of Fenfluramine and Norfenfluramine in Mice: Is l-Norfenfluramine a Better Follow-Up Compound to Racemic-Fenfluramine?
Natalia Erenburg, Emilio Perucca, Jeff Bechard, et al.
(2023)
Open Access | Times Cited: 1
How Has the Treatment of Polish Children with Dravet Syndrome Changed? Future Perspectives
A Zielińska, Urszula Skarżyńska, Paulina Górka-Skoczylas, et al.
Biomedicines (2024) Vol. 12, Iss. 6, pp. 1249-1249
Open Access
Avances y orientaciones en el tratamiento de la epilepsia farmacorresistente: revisión de los nuevos fármacos cenobamato, fenfluramina y cannabidiol por la Sociedad Andaluza de Epilepsia
C. Arenas-Cabrera, Pablo Cabezudo‐García, Rocío Calvo Medina, et al.
Revista de Neurología (2024) Vol. 79, Iss. 06, pp. 161-161
Closed Access
Antiseizure medications
Mei T. Liu, Daniel Greer, Megan Maroney
Side effects of drugs annual (2024), pp. 69-111
Closed Access
Drug-resistant epilepsy: Is there an overlooked association between drug resistant epilepsies and neuropsychiatric comorbidities?
Alan Talevi
Epilepsy & Behavior (2024) Vol. 161, pp. 110144-110144
Closed Access
Page 1

Scroll to top